ArriVent BioPharma (AVBP) Competitors $20.43 +0.44 (+2.18%) As of 12:38 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVBP vs. QURE, CNTA, XENE, GMTX, TARS, RARE, CGON, MOR, KNSA, and HCMShould you be buying ArriVent BioPharma stock or one of its competitors? The main competitors of ArriVent BioPharma include uniQure (QURE), Centessa Pharmaceuticals (CNTA), Xenon Pharmaceuticals (XENE), Gemini Therapeutics (GMTX), Tarsus Pharmaceuticals (TARS), Ultragenyx Pharmaceutical (RARE), CG Oncology (CGON), MorphoSys (MOR), Kiniksa Pharmaceuticals International (KNSA), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry. ArriVent BioPharma vs. Its Competitors uniQure Centessa Pharmaceuticals Xenon Pharmaceuticals Gemini Therapeutics Tarsus Pharmaceuticals Ultragenyx Pharmaceutical CG Oncology MorphoSys Kiniksa Pharmaceuticals International HUTCHMED uniQure (NASDAQ:QURE) and ArriVent BioPharma (NASDAQ:AVBP) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability. Which has more risk and volatility, QURE or AVBP? uniQure has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500. Comparatively, ArriVent BioPharma has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Does the media refer more to QURE or AVBP? In the previous week, uniQure had 1 more articles in the media than ArriVent BioPharma. MarketBeat recorded 6 mentions for uniQure and 5 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 0.83 beat uniQure's score of 0.53 indicating that ArriVent BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment uniQure 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ArriVent BioPharma 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is QURE or AVBP more profitable? ArriVent BioPharma has a net margin of 0.00% compared to uniQure's net margin of -1,387.98%. ArriVent BioPharma's return on equity of -55.40% beat uniQure's return on equity.Company Net Margins Return on Equity Return on Assets uniQure-1,387.98% -1,010.74% -33.27% ArriVent BioPharma N/A -55.40%-51.97% Do institutionals & insiders hold more shares of QURE or AVBP? 78.8% of uniQure shares are held by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are held by institutional investors. 4.8% of uniQure shares are held by insiders. Comparatively, 18.6% of ArriVent BioPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has stronger valuation & earnings, QURE or AVBP? ArriVent BioPharma has lower revenue, but higher earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatiouniQure$27.12M123.48-$239.56M-$3.92-15.57ArriVent BioPharmaN/AN/A-$80.49M-$4.02-5.08 Do analysts recommend QURE or AVBP? uniQure presently has a consensus price target of $71.75, suggesting a potential upside of 17.56%. ArriVent BioPharma has a consensus price target of $39.14, suggesting a potential upside of 91.55%. Given ArriVent BioPharma's higher possible upside, analysts plainly believe ArriVent BioPharma is more favorable than uniQure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score uniQure 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.83ArriVent BioPharma 2 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.67 SummaryArriVent BioPharma beats uniQure on 8 of the 15 factors compared between the two stocks. Get ArriVent BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AVBP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVBP vs. The Competition Export to ExcelMetricArriVent BioPharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$829.23M$3.40B$6.05B$10.50BDividend YieldN/A2.30%5.73%4.80%P/E Ratio-5.0822.8585.1627.28Price / SalesN/A269.65518.10200.08Price / CashN/A46.9537.5761.53Price / Book2.6710.5412.406.82Net Income-$80.49M-$52.58M$3.32B$276.69M7 Day Performance-1.85%0.57%0.52%0.18%1 Month Performance7.84%15.45%10.05%8.18%1 Year Performance-28.07%17.98%75.51%34.82% ArriVent BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVBPArriVent BioPharma2.0902 of 5 stars$20.44+2.2%$39.14+91.5%-28.4%$829.23MN/A-5.0840Analyst DowngradeQUREuniQure3.5122 of 5 stars$56.70+7.2%$71.75+26.5%+945.4%$3.13B$27.12M-14.54500CNTACentessa Pharmaceuticals2.8365 of 5 stars$23.01+0.0%$32.38+40.7%+34.5%$3.08B$6.85M-12.86200XENEXenon Pharmaceuticals2.4884 of 5 stars$38.95-1.5%$53.30+36.8%-2.8%$3.00B$7.50M-10.97210Analyst ForecastGMTXGemini TherapeuticsN/A$69.28+2.2%N/A+50.7%$3.00BN/A-69.2830TARSTarsus Pharmaceuticals0.6834 of 5 stars$68.77+1.6%$66.67-3.1%+91.4%$2.91B$182.95M-29.6450RAREUltragenyx Pharmaceutical4.357 of 5 stars$29.98-0.7%$81.50+171.8%-43.6%$2.89B$610.16M-5.431,294News CoverageInsider TradeAnalyst RevisionCGONCG Oncology2.1802 of 5 stars$37.67-1.2%$56.55+50.1%+14.2%$2.87B$551K-21.2861MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730KNSAKiniksa Pharmaceuticals International3.9211 of 5 stars$38.26-0.1%$44.29+15.8%+42.3%$2.84B$529.33M956.86220Trending NewsAnalyst ForecastAnalyst RevisionHCMHUTCHMED2.5221 of 5 stars$16.09-0.8%$20.88+29.8%-22.5%$2.80B$602.20M0.001,811 Related Companies and Tools Related Companies uniQure Competitors Centessa Pharmaceuticals Competitors Xenon Pharmaceuticals Competitors Gemini Therapeutics Competitors Tarsus Pharmaceuticals Competitors Ultragenyx Pharmaceutical Competitors CG Oncology Competitors MorphoSys Competitors Kiniksa Pharmaceuticals International Competitors HUTCHMED Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVBP) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ArriVent BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ArriVent BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
